This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Jolie Siegel Biography and Net Worth

Insider of C4 Therapeutics

Jolie Siegel joined C4 Therapeutics in July 2020 as our Chief Legal Officer and also serves as our Secretary. Previously, Jolie served as General Counsel and Secretary at Neon Therapeutics, an immune oncology company focused on developing personalized cancer vaccines and T cell therapies, a role she held through the sale of Neon to BioNTech SE in May 2020. Prior to Neon, Jolie was the Senior Vice President, Deputy General Counsel and Assistant Secretary of Intralinks, a financial technology provider for the global banking, deal making and capital markets communities, a role she held through the sale of the company in 2017. Prior to her time in-house, she was a partner at Choate, Hall & Stewart LLP where she worked on corporate transactional, securities and general business matters, with an emphasis on private equity, venture capital and high-growth companies in life sciences and a range of other industries. Jolie started her legal career at Testa, Hurwitz & Thibeault, LLP, where she was a member of the business practice group. Jolie holds a J.D. from the University of Pennsylvania Law School and a B.A., cum laude, from the University of Pennsylvania.

How old is Jolie Siegel?: Ms. Siegel is currently 47 years old. There are 6 older executives and no younger executives at C4 Therapeutics. The oldest executive at C4 Therapeutics is Dr. Kenneth C. Anderson M.D., Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board, who is 73 years old. Learn More on Jolie Siegel's age.
How do I contact Jolie Siegel?: The corporate mailing address for Ms. Siegel and other C4 Therapeutics executives is , , . C4 Therapeutics can also be reached via phone at 617-231-0700 and via email at [email protected]. Learn More on Jolie Siegel's contact information.
Has Jolie Siegel been buying or selling shares of C4 Therapeutics?: Jolie Siegel has not been actively trading shares of C4 Therapeutics during the past quarter. Most recently, Jolie Siegel sold 12,500 shares of the business's stock in a transaction on Thursday, July 29th. The shares were sold at an average price of $45.00, for a transaction totalling $562,500.00. Learn More on Jolie Siegel's trading history.
Who are C4 Therapeutics' active insiders?: C4 Therapeutics' insider roster includes Adam Crystal (Insider), Stewart Fisher (Insider), Elena Prokupets (Director), Malcolm Salter (Director), and Jolie Siegel (Insider). Learn More on C4 Therapeutics' active insiders.

Jolie Siegel Insider Trading History at C4 Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/29/2021	Sell	12,500	$45.00	$562,500.00

Jolie Siegel Buying and Selling Activity at C4 Therapeutics

C4 Therapeutics Company Overview

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $4.21

$4.08

$4.29

50 Day Range

MA: $5.48

$4.01

$7.00

2 Week Range

Now: $4.21

$1.06

$11.88

Volume

620,742 shs

Average Volume

2,080,657 shs

Market Capitalization

$297.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.93

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad